'Acute on chronic' effect of depot leuprolide in patients with stage D2 cancer of prostate.

R. Sharifi, M. Soloway, M. Clayton, A. Mounzer, M. Strub, P. Siami, M. Lee

Research output: Contribution to journalArticlepeer-review

3 Scopus citations


During a phase III open study of depot leuprolide for stage D2 cancer of the prostate, we studied the effect of depot leuprolide on chronic leuprolide users. To determine whether there was a transient elevation of testosterone or luteinizing hormone (LH) 4-24 h and 3-5 days following the monthly injections, we monitored the changes of testosterone and LH before injection and 24 h post-injection in 10 patients who have been under depot leuprolide Rx for 24-36 weeks, and in 35 patients before injection and 3-5 days post-injection who have received depot leuprolide for 8-24 weeks prior to monitoring. Comparison of the data between pre-injection within 24 h and 3-5 days post-injection showed no significant changes of testosterone and LH values between these levels for either testosterone (P = 0.31) or LH (P = 0.45). We therefore conclude that there was no 'acute on chronic' effect of depot formulation in chronic users of depot leuprolide.

Original languageEnglish (US)
Pages (from-to)29-31
Number of pages3
JournalAnti-cancer drugs
Issue number1
StatePublished - Oct 1990
Externally publishedYes

ASJC Scopus subject areas

  • Oncology
  • Pharmacology
  • Pharmacology (medical)
  • Cancer Research


Dive into the research topics of ''Acute on chronic' effect of depot leuprolide in patients with stage D2 cancer of prostate.'. Together they form a unique fingerprint.

Cite this